Sarepta Therapeutics, Inc.

SRPT · Nasdaq · SIC 2834: Pharmaceutical Preparations
314
SEC Filings

Business Summary

PART I . Overview We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, differentiated and innovative technologies, and through collaborations with our strategic partners, we have developed multiple approved products for the treatment of Duchenne muscular ...

Next Earnings

Q2 FY2026 — expected 2026-08-18

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSRPTdiscussed_in_filing Cybersecurity
topic_mentionSRPTdiscussed_in_filing Cybersecurity
topic_mentionSRPTdiscussed_in_filing Healthcare & Bio
topic_mentionSRPTdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-022025-12-310001193125-26-084144EDGAR118K words
2025-02-282024-12-310000950170-25-029973EDGAR—
2024-02-282023-12-310000950170-24-022036EDGAR—
2023-02-282022-12-310000950170-23-005062EDGAR—
2022-03-012021-12-310000950170-22-002517EDGAR—
2021-03-012020-12-310001564590-21-009835EDGAR—
2020-02-262019-12-310001564590-20-006769EDGAR—
2019-02-282018-12-310001564590-19-005170EDGAR—
2018-03-012017-12-310001564590-18-004107EDGAR—
2017-02-282016-12-310001564590-17-002842EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-269436EDGAR74K words
2025-08-062025-06-300000950170-25-103971EDGAR—
2025-05-062025-03-310000950170-25-064412EDGAR—
2024-11-062024-09-300000950170-24-122239EDGAR—
2024-08-072024-06-300000950170-24-092720EDGAR—
2024-05-012024-03-310000950170-24-051234EDGAR—
2023-11-012023-09-300000950170-23-057414EDGAR—
2023-08-022023-06-300000950170-23-037125EDGAR—
2023-05-022023-03-310000950170-23-016654EDGAR—
2022-11-022022-09-300000950170-22-021213EDGAR—
2022-08-022022-06-300000950170-22-013863EDGAR—
2022-05-042022-03-310000950170-22-007375EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-02-250001193125-26-072064EDGAR0K words
2026-02-250001193125-26-071566EDGAR—
2026-01-120001193125-26-010116EDGAR—
2025-12-190001193125-25-326969EDGAR—
2025-12-110001193125-25-315032EDGAR—
2025-12-080001193125-25-310588EDGAR—
2025-11-030001193125-25-262591EDGAR—
2025-08-290001193125-25-192794EDGAR—
2025-08-210001193125-25-184625EDGAR—
2025-08-130001193125-25-179819EDGAR—

314 total filings indexed. 282 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0000873303
TickerSRPT
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: cf957b386447d0afebfac83953437986cccbcd4491fe2feb02c3f33a371da143
parent: f2b30aa92d64ca60f0cfd9787273c6eefa694dac8d89bca6dc3bfbf2f23524b9
content hash: 4f2b883e765441de011b6175bd0821191b2051f6beca052cb73f8b5f2df584b2
signed: 2026-04-13T04:47:36.027Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf